tag:blogger.com,1999:blog-16207375070656001232024-03-13T17:11:26.870+00:00Pharmamicspharmaceutical news,pharmaceutical sites, pharmaceutical links,pharmaceutical company,pharmaceutical journals,pharmaceuticals,pharma,drug,pharmaceutical technology,pharmaceutical jobs,biotechnology and healthcare,industry sectors,pharmaceutical industry,pharmaceutical reports,biotechnology reports,biotechnology news,biotechnology company,biotechnology reports,healthcare industry,healthcare news,healthcare company,healthcare reports,industry news,industry research,company researchUnknownnoreply@blogger.comBlogger800125tag:blogger.com,1999:blog-1620737507065600123.post-12538188985933270932012-09-08T08:36:00.000+01:002012-09-08T08:38:38.039+01:00Alimta regimen didn't meet goal in study
Eli Lilly and Co. said Thursday a drug regimen including its Alimta therapy did not improve the survival of lung cancer patients in a late-stage clinical trial.
Lilly said patients who were treated with a combination of Alimta, Avastin, and the chemotherapy drug carboplatin lived for 12.6 months after the start of treatment. Patients who were treated with chemotherapy and Avastin, a drugUnknownnoreply@blogger.com0tag:blogger.com,1999:blog-1620737507065600123.post-30137283449748513832010-11-26T06:44:00.000+00:002010-11-26T06:56:30.759+00:00HIV Drug Reduces Transmission Among Men By Over 40%, Study FindsA daily dose of antiretroviral medication lowered the risk of contracting HIV by more than 40% among men who have sex with men, according to a study published Tuesday in the New England Journal of Medicine, the New York Times reports.The results of the study -- nicknamed iPrEx -- "are the best news in the AIDS field in years" and "could change the battle" against HIV/AIDS, according to the Times Unknownnoreply@blogger.com2tag:blogger.com,1999:blog-1620737507065600123.post-18241567835136502872010-11-26T06:31:00.000+00:002010-11-26T06:41:46.094+00:00Breastfeeding While Taking Seizure Drugs May Not Harm Childs IQ, Study Suggests"While more research is needed with larger numbers of women and their babies, these results are reassuring to women who want to give their babies all the benefits of breastfeeding but also need to remain on their epilepsy medications to avoid devastating seizures," said study author Kimford Meador, MD, of Emory University in Atlanta and a Fellow of the American Academy of Neurology (AAN).The Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-1620737507065600123.post-65743125819413240472010-11-26T04:35:00.000+00:002010-11-26T06:04:37.197+00:00No Link Between Heartburn Drugs and Birth Defects: StudyBabies born to women who took a popular class of heartburn drugs while they were pregnant did not appear to have any heightened risk of birth defects, a large Danish study finds.This class of drugs, known as proton-pump inhibitors (PPIs), include blockbusters such as Prilosec (omeprazole), Prevacid (lansoprazole) and Nexium (esomeprazole). All were available by prescription-only during most of Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-1620737507065600123.post-84710122283330976702010-09-17T17:59:00.000+01:002010-09-17T18:05:45.801+01:00In Early Trial, Targeted Therapy Fights Advanced MelanomaBy probing deeper into the biological mechanisms that go awry in melanoma, scientists have come up with an experimental drug that has had an effect in a surprising number of patients with advanced melanoma.The drug, PLX4032, just completed a phase 1 clinical trial in which 81 percent of participants with a particular gene mutation had a partial response, meaning at least some shrinkage of the Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-1620737507065600123.post-83986893381063044862010-09-17T17:46:00.000+01:002010-09-17T17:58:32.879+01:00Findings May Lead to First Approved Treatment for MyelofibrosisMyelofibrosis is a rare but serious disorder in which the bone marrow is replaced by scar tissue. There is no currently approved treatment for the disease, but a phase I/II clinical study of an experimental drug produced by Incyte Corp. of Delaware may possibly lead to the first medical option to reduce spleen size.One of the primary symptoms of myelofibrosis is an enlarged spleen. Because the Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-1620737507065600123.post-69090671186547902592010-09-15T15:05:00.000+01:002010-09-15T15:16:29.433+01:00Ticagrelor : New hope for heart attack patientsA major drug trial has brought scientists closer to making a drug that could prevent thousands of deaths from heart attacks.From the past six years, international clinical trials have been going on a new drug, ticagrelor.The new findings have revealed that the platelet function in patients taking ticagrelor recovered much quicker after the drug is stopped, compared to the current gold standard Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-1620737507065600123.post-12712784814316332372010-09-15T14:56:00.000+01:002010-09-15T15:01:51.107+01:00The FDA approves new drug for goutThe Food and Drug Administration said Tuesday that it has approved a new drug to treat gout in patients who do not respond to existing therapy. The drug is called Krystexxa and is manufactured by Savient Pharmaceuticals Inc. of East Brunswick, N.J. The FDA had rejected the drug in August of 2009 because of manufacturing problems.In a letter to the company then, the agency said that the potential Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-1620737507065600123.post-26482440219392413902010-09-15T14:46:00.000+01:002010-09-15T14:55:21.563+01:00Scientists In Singapore Discover New Drug Against MalariaScientists from the Singapore Immunology Network (SIgN) of Singapore’s Agency of Science, Technology and Research’s (A*STAR) led by Dr Laurent Renia have made a breakthrough concerning a drug that is effective against malaria.Their work, carried out with industry leader Novartis, the Swiss Tropical and Public Health Institute, and The Scripps Research Institute, was published in top scientific Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-1620737507065600123.post-63405703091053189322010-09-14T14:14:00.000+01:002010-09-14T14:20:16.687+01:00New Drug Speeds Response in multidrug-resistant TBPatients with multidrug-resistant TB (MDR-TB) given a new anti-TB drug -- TMC207 -- combined with a background regimen, responded almost twice as fast as those on placebo with the background regimen, a researcher reported here.Final results from the first part of a stage IIb trial among 47 patients, found the median time to culture conversion was 11 weeks for those treated for eight weeks with Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-1620737507065600123.post-31072865093795455072010-09-14T13:46:00.000+01:002010-09-14T14:09:44.873+01:00Rosuvastatin cuts risk of catching pneumonia, study findsPatients taking AstraZeneca Plc’s cholesterol-lowering medicine Crestor (Rosuvastatin) in a study were less likely to develop pneumonia, a finding that potentially will broaden use of such drugs.The result supports earlier research suggesting drugs in this class, called statins, prevent deaths from pneumonia. The latest study, an analysis of a 17,000-person clinical trial that ended in 2008, was Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-1620737507065600123.post-56772167479728541872010-09-13T11:34:00.000+01:002010-09-13T11:42:04.173+01:00Avandia Continues to Face Scrutiny: Biotech's Latest MishapsGlaxoSmithKline’s (GSK) diabetes drug Avandia is once again under regulatory scrutiny—this time it’s in Europe where the European Medicines Agency met to discuss whether Avandia should continue to be marketed. The agency in a press statement said that no final decision has been made about the drug.It said it has further questions for GSK before deciding whether and what action needs to be taken. Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-1620737507065600123.post-78711662875054576762010-09-13T11:27:00.000+01:002010-09-13T11:32:01.724+01:00Novartis's Experimental Meningitis Vaccine Meets Goals in Late-Stage StudyNovartis AG said an experimental meningitis B vaccine met the goals of a late-stage clinical study.The vaccine, called 4CMenB, achieved a “robust immune response” in the study of more than 3,600 infants, the Basel, Switzerland-based company said today in an e-mailed statement. The drug also had “an acceptable” side-effect profile, the company said.Novartis expects the results of additional Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-1620737507065600123.post-18658589913189721932010-09-13T11:19:00.000+01:002010-09-13T11:22:12.708+01:00Some patients with severe heart disease receiving wrong treatment, study findsTens or even hundreds of thousands of Americans are having coronary artery angioplasty and stenting every year when they should be having bypass grafts, and the result is an extra 5,000 or more deaths annually, researchers said Sunday.Patients and cardiologists frequently prefer angioplasty and the insertion of a stent to keep arteries open because it is quicker and easier; patients go home Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-1620737507065600123.post-12120648115163098602010-09-12T08:36:00.000+01:002010-09-12T08:42:17.846+01:00New drug hope for pancreatic cancerA commonly used chemotherapy drug may offer a new lifeline to sufferers of one of the most deadly cancers, research has shown.Trial results suggest that the drug 5-fluorouracil (5-FU) is an effective alternative for pancreatic cancer patients who fail to respond to standard treatment.They also raise hopes of providing better therapy by combining the two drugs.A study now under way is looking at Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-1620737507065600123.post-75628105699623548352010-09-12T08:16:00.000+01:002010-09-12T08:29:10.197+01:00Dapagliflozin is a new drug for the treatment of type two diabetesA strange drug, the premier in its class, gives added blood sugar dominate to mobile vulgus with category 2 diabetes who are already enchanting the glucose-lowering medication metformin.The budding agent, dapagliflozin, which also helped patients squander weight, is novel in that it does not produce directly on the body’s insulin mechanisms, according to a inspect appearing in the June 26 issue Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-1620737507065600123.post-14179212104471162372010-09-10T19:58:00.000+01:002010-09-10T20:02:04.714+01:00Potential new drug for neurodegenerative diseasesA research team has identified a small molecule that helps human cells get rid of the misfolded, disfigured proteins implicated in Alzheimer's disease and other neurodegenerative ailments.potential drug could have applications for other conditions as well.Cells create and discard proteins continuously, a process that relies on a balance between the speed with which new proteins are created and Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-1620737507065600123.post-84324060921032223722010-09-10T19:52:00.000+01:002010-09-10T19:56:50.000+01:00New emergency contraceptive approved by FDAThe newest form of emergency contraceptive, ellaOne, was approved August 13 by the U.S. Food and Drug Administration.Although the new drug has been around since fall of 2009 in select European countries, it was not introduced to the United States until June 2010.The new drug is a type of emergency contraceptive pill that allows a woman up to five days after sexual intercourse to consume the Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-1620737507065600123.post-34281797137150777322010-09-10T19:40:00.000+01:002010-09-10T19:43:12.683+01:00Promising Treatment for Metastatic MelanomaResearchers from the John Theurer Cancer Center at Hackensack University Medical Center played an important role in a study that led to the Food & Drug Administration's (FDA) recent fast tracking of ipilimumab, a promising treatment for metastatic melanoma.The FDA based its decision largely on the results of a pivotal study published in the New England Journal of Medicine on August 19, 2010 -Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-1620737507065600123.post-66546271185434035232010-05-25T07:17:00.000+01:002010-05-25T07:20:43.048+01:00Researchers try new approaches to preventing HIVTablets, insertable rings and dissolving films can effectively deliver drugs to help protect women and perhaps men from infection with the AIDS virus, researchers reported on Monday.They also found evidence that using such an approach -- called a microbicide -- may help overcome some of the risks of drug resistance that can come with taking pills to prevent infection.Here are some of the findingsUnknownnoreply@blogger.com2tag:blogger.com,1999:blog-1620737507065600123.post-33496849827419961322010-05-25T07:02:00.000+01:002010-05-25T07:15:35.129+01:00Dutch study say that using Beta-Blockers is safe for LungsMedical tradition says that the beta blockers used to treat heart disease shouldn't be given to people who also have severe lung disease, but a new Dutch study suggests the tradition is wrong.A study of more than 2,200 people with chronic obstructive pulmonary disease (COPD), a diagnosis that includes emphysema and chronic bronchitis, found better survival among those given beta blockers than Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-1620737507065600123.post-80819092660510487612010-05-20T21:20:00.000+01:002010-05-20T21:22:47.086+01:00Merck-Cardiome heart rhythm drug meets study goalsMerck & Co. and Cardiome Pharma Corp. said Friday that their drug candidate Brinavess met its goal in a late-stage clinical study, as it was better at restoring a steady heartbeat than an older drug use for the same purpose.The trial compared Brinavess to the standard drug, amiodarone, as a treatment for atrial fibrillation. Atrial fibrillation is a condition in which the upper chambers of Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-1620737507065600123.post-86560342969482685572010-05-20T21:12:00.000+01:002010-05-20T21:18:55.501+01:00Trials begin on hepatitis C drugThe first human clinical trials have started on a new drug developed to treat infections caused by the hepatitis C virus.The medication, taken orally, was first prepared at the Welsh School of Pharmacy at Cardiff University in 2008.Laboratory tests showed it killed 90% of the virus at very low concentration.Trials in healthy volunteers to assess the drug's safety are being held before its Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-1620737507065600123.post-29616236514628665922010-05-20T21:02:00.000+01:002010-05-20T21:05:37.175+01:00Rotavirus vaccines reduce hospitalizations in kidsThe introduction of the first rotavirus vaccine in the United States in 2006 led to sharp reductions in hospitalizations for gastroenteritis, an inflammation of the stomach and intestines that is marked by diarrhea and dehydration, researchers reported Wednesday. Rotavirus is one of the leading causes of gastroenteritis and was thought to be the cause of an estimated 55,000 to 70,000 Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-1620737507065600123.post-50278151238330280192010-05-20T20:55:00.000+01:002010-05-20T21:00:03.952+01:00Sanofi-Aventis Begins Study Of Heart Drug Multaq In 10,000 Patients For Expanded UsePharmaceutical company Sanofi-Aventis Wednesday said it has initiated a Phase IIIb trial of Multaq in over 10 thousand patients with permanent atrial fibrillation or abnormal heart rhythm. The Paris, France-based company’s study is focused on assessing the potential clinical benefit of the drug in reducing major adverse cardiovascular events, and it expects first patient enrollment to begin in Unknownnoreply@blogger.com0